Study to Evaluate Efficacy of Telehealth Cognitive Behavioral Therapy for Migraine
August 11th 2022Study will analyze whether cognitive behavioral therapy telehealth can lower headache days and disability as effectively as cognitive behavioral therapy plus a preventive medication for migraine.
Read More
Survey Finds Strong Link Between Migraine Symptoms and Mental Health
August 10th 2022Survey finds that 91% of health care providers and 67% of people with migraines feel that individuals who are able to successfully manage stress and mental health conditions can also better manage the symptoms of migraine.
Read More
Pediatric Hepatitis Levels Remain Consistent With Pre-Pandemic Levels
July 12th 2022Hepatitis-associated emergency department visits and hospitalizations, liver transplantations, and adenovirus stool testing results in pediatric patients were not found to increase during the COVID-19 pandemic.
Read More
FDA Approves Lisocabtagene Maraleucel for Second-Line Large B-cell Lymphoma
June 27th 2022Lisocabtagene maraleucel (liso-cel, Breyanzi; Bristol Myers Squibb) approved for the second-line treatment of patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, and follicular lymphoma grade 3B.
Read More
FDA Approves Expanded Indication for Vaxneuvance Pneumococcal Vaccine
June 22nd 2022Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older.
Read More
FDA Advisory Committee Recommends EUA for Novavax COVID-19 Vaccine
June 8th 2022The FDA Vaccines and Related Biological Products Advisory Committee voted nearly unanimously for an emergency use authorization for the Novavax COVID-19 vaccine, NVX-CoV2373, for use in individuals 18 years of age and older.
Read More